Bausch Sues Turkish Firm to Block Copies of Blockbuster Xifaxan

A Turkish company’s proposed copy of Xifaxan’s 550-milligram tablet infringes four patents for Bausch Health Cos.’ blockbuster drug, which treats irritable bowel syndrome with diarrhea, a federal lawsuit said.

Two of Bausch Health’s Salix Pharmaceuticals units allege that Saba Ilac Sanayi ve Ticaret AS infringes US Patent Nos. 11,564,912, 11,779,571, 8,193,196, and 7,928,115 with its generic rifaximin, Xifaxan’s active ingredient, according to a complaint filed April 4 in the US District Court for the District of New Jersey. Saba’s copies would be used to treat IBS-D, the suit said.

The ‘912 and ‘571 patents expire in February ...